

Ranibizumab for treating diabetic macular oedema (rapid review of technology appraisal guidance 237)

Issued: February 2013

NICE technology appraisal guidance 274

guidance.nice.org.uk/ta274









1 Guidance

This guidance replaces NICE technology appraisal guidance 237 (published in November 2011). For details see [About this guidance](#).


- 1.1 Ranibizumab is recommended as an option for treating visual impairment due to diabetic macular oedema only if:
 - the eye has a central retinal thickness of 400 micrometres or more at the start of treatment and
 - the manufacturer provides ranibizumab with the discount agreed in the patient access scheme (as revised in 2012).
- 1.2 People currently receiving ranibizumab for treating visual impairment due to diabetic macular oedema whose disease does not meet the criteria in 1.1 should be able to continue treatment until they and their clinician consider it appropriate to stop.


Macula Thickness : Macular Cube 512x128

OD ● ○ OS



Diversified Distribution of Normals



	Central Subfield Thickness (μm)	Cube Volume (mm^3)	Cube Average Thickness (μm)
ILM - RPE	364	10.5	291

Macular Change: Macular Cube 512x128

OD ● ○

Registration : Automatic




Registration succeeded

Exam from 22/06/2011 03:31


Exam from 10/07/2012 13:15

Fovea: 259, 63

Fovea: 259, 63




Overlay: OCT Fundus Transparency: 0 %



Overlay: ILM-RPE Difference Transparency: 0 %

Extracted B-Scan






Lucentis Regime

- 3 Loading doses
- PRN – 7 in first year, 4 second, 3 third
- Injection or Monthly observations
- Laser PRN


- Significant Rise in workload

3 Lucentis (Ranibizumab)

0.9 to 0.6 = 15 letters




Overlay: OCT Fundus Transparency: 0 %




Overlay: ILM-RPE Difference Transparency: 0 %

Extracted B-Scan





55 NIDDM

Laser to the Right eye x1 0.12 VA



-0.08 R

0.24 Left



Assessments

- History
- HBA1c, Lipids
- Blood Pressure
- Photographs each visit
 - Manipulate to Black and white
- OCT – Each visit
 - Change analysis
- FFA as needed
 - At start of Lucentis (Ranibizumab)
 - Failed Laser
 - Looking for New vessels or ischemia.
- Report to DRSS

That's all Folks!

- www.nicholaslee.co.uk
- Lectures.
- Handouts.